James A. Hendrix

Biography

As a member of Medical and Scientific Relations Division, Dr. Hendrix provides leadership on specific domestic and international efforts to advance the science agenda for the division. Critical elements of his role include managing industry consortia such as the Alzheimer’s Association Research Roundtable, leading the Global Biomarker Standardization Consortium, and assisting with the coordination of National Alzheimer’s Plan efforts on behalf of Medical and Scientific Relations. Dr. Hendrix earned his Ph.D. degree from Colorado State University, where he also completed a postdoctoral fellowship in organic chemistry. Before joining the Alzheimer’s Association, Dr. Hendrix was a pharmaceutical scientist with a focus on medicinal chemistry and drug discovery for central nervous system (CNS) diseases. Dr. Hendrix spent 18 years at Sanofi-Aventis and predecessor companies, where he rose to the level of Senior Director, U.S. Site Head for CNS Research. During his tenure at Sanofi-Aventis, Dr. Hendrix led teams and groups that advanced two compounds into the clinic (to date) and 13 compounds into pre-clinical development. These teams and groups also identified 23 chemical series for compound optimization. Dr. Hendrix spent 2 years in the biotechnology industry with various companies including Oligomerix, whose research focuses on tau-based therapies for the treatment of Alzheimer’s disease. Dr. Hendrix is a co-author on numerous publications and patents focused on treatments for CNS diseases.  

Research Interest

Prosthodontic and retroflex.